{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:28:12Z","timestamp":1790220492462,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaad.2026.01.075","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:08:01Z","timestamp":1779883681000},"page":"S35-S42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Systemic therapies for atopic dermatitis"],"prefix":"10.1016","volume":"94","author":[{"given":"Rame","family":"Yousif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dareen","family":"Elgindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2026.01.075_bib1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.01.075_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s13555-023-00894-3","article-title":"Dupilumab demonstrates rapid onset of action in improving signs, symptoms and quality of life in adults with atopic dermatitis","volume":"13","author":"Augustin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.075_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.075_bib4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.anai.2025.06.020","article-title":"New treatments in atopic dermatitis update","volume":"135","author":"Gallagher","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.075_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.075_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40257-023-00785-5","article-title":"Efficacy and safety of abrocitinib in patients with severe and\/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial","volume":"24","author":"Simpson","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.01.075_bib7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1159\/000543397","article-title":"Upadacitinib and dupilumab demonstrate superior efficacy in the treatment of adolescent atopic dermatitis: a network meta-analysis","volume":"186","author":"Zhao","year":"2025","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.075_bib8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s13555-024-01158-4","article-title":"Lebrikizumab provides rapid clinical responses across all eczema area and severity index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis","volume":"14","author":"Simpson","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10451","key":"10.1016\/j.jaad.2026.01.075_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jaad.2026.01.075_bib10","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.17218","article-title":"Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI \u2265 16) analysis of randomized phase 2B study","volume":"35","author":"Silverberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.075_bib11","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13555-024-01157-5","article-title":"Upadacitinib rapidly improves patient-reported outcomes in atopic dermatitis: 16-week results from phase 3 clinical trials (measure up 1 and 2)","volume":"14","author":"Simpson","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10290","key":"10.1016\/j.jaad.2026.01.075_bib12","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40257-022-00738-4","article-title":"Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate-to-severe atopic dermatitis: subgroup analysis of the randomized phase III JADE COMPARE trial","volume":"24","author":"St\u00e4nder","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.01.075_bib14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s13555-021-00534-8","article-title":"Itch and sleep improvements with baricitinib in patients with atopic dermatitis: a post hoc analysis of 3 phase 3 studies","volume":"11","author":"Buhl","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"10.1016\/j.jaad.2026.01.075_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.anai.2024.05.014","article-title":"A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: a position paper of the American College of Allergy, Asthma and Immunology","volume":"133","author":"Lieberman","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2026.01.075_bib16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","article-title":"Therapeutic pipeline for atopic dermatitis: end of the drought?","volume":"140","author":"Paller","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.075_bib17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2026.01.075_bib18","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s40265-024-02095-4","article-title":"Emerging biologic therapies for the treatment of atopic dermatitis","volume":"84","author":"Alvarenga","year":"2024","journal-title":"Drugs"},{"issue":"10356","key":"10.1016\/j.jaad.2026.01.075_bib19","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2026.01.075_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/pai.70045","article-title":"Comparative efficacy of biologics and small molecule drugs in treating pediatric atopic dermatitis in patients aged 2-18 years: a 12-16 week network meta-analysis of randomized controlled trials","volume":"36","author":"Yong","year":"2025","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.01.075_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2026.01.075_bib23","article-title":"Ocular adverse effects in atopic dermatitis patients treated with dupilumab: a bibliometric analysis","volume":"9","author":"Jia","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.jaad.2026.01.075_bib24","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/jdv.15608","article-title":"Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion","volume":"33","author":"Thyssen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"24","key":"10.1016\/j.jaad.2026.01.075_bib25","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2026.01.075_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.01.075_bib27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.075_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40257-024-00859-y","article-title":"Dupilumab safety and efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study","volume":"25","author":"Paller","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.01.075_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","article-title":"Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)","volume":"159","author":"Simpson","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.01.075_bib30","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.01.075_bib31","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jamadermatol.2023.2626","article-title":"Safety and efficacy of tralokinumab in older adults with moderate-to-severe atopic dermatitis: a secondary analysis","volume":"159","author":"Merola","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.01.075_bib32","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.075_bib33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","article-title":"Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial","volume":"87","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.01.075_bib34","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.075_bib36","article-title":"Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan","author":"Sasaki","year":"2025","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2026.01.075_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdcr.2025.03.026","article-title":"A case of concurrent exacerbation of manifestations and asthma after the initiation of nemolizumab treatment for atopic dermatitis","volume":"61","author":"Katsuta","year":"2025","journal-title":"JAAD Case Rep"},{"issue":"8","key":"10.1016\/j.jaad.2026.01.075_bib38","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/bjd\/ljaf045","article-title":"Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged \u2265 13 years: efficacy and safety data from a phase II\/III study","volume":"193","author":"Yokozeki","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2026.01.075_bib40","series-title":"Nemolizumab-ilto [package insert]","year":"2024"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jaad.2026.01.075_bib43","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10290","key":"10.1016\/j.jaad.2026.01.075_bib44","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"10246","key":"10.1016\/j.jaad.2026.01.075_bib45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2026.01.075_bib46","first-page":"702","article-title":"Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab","volume":"23","author":"Wu","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.jaad.2026.01.075_bib47","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaad.2023.05.001","article-title":"Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study","volume":"89","author":"Chiricozzi","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.075_bib48","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2026.01.075_bib49","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2025.04.042","article-title":"Deciding which patients with atopic dermatitis to prioritize for biologics and Janus kinase inhibitors","volume":"13","author":"Kamata","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2026.01.075_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1365544","article-title":"Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks","volume":"15","author":"Hagino","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2026.01.075_bib51","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/1346-8138.17173","article-title":"Real-world effectiveness and safety of abrocitinib in 12 Japanese patients with atopic dermatitis and transcriptome analysis with peripheral blood","volume":"51","author":"Uchiyama","year":"2024","journal-title":"J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.01.075_bib52","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.16763","article-title":"Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan","volume":"50","author":"Hagino","year":"2023","journal-title":"J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.01.075_bib53","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1111\/jdv.19862","article-title":"Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: a 16-week multicentre retrospective study","volume":"38","author":"Gargiulo","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies","volume":"151","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13555-023-01071-2","article-title":"Safety and efficacy of upadacitinib for atopic dermatitis in Japan: analysis of the 3-year phase 3 rising up study","volume":"14","author":"Katoh","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.075_bib56","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","article-title":"Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure","volume":"25","author":"Simpson","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib57","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2411834","article-title":"Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years","volume":"35","author":"Wollenberg","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib58","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2022.2161812","article-title":"Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials","volume":"34","author":"Bieber","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.075_bib59","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.075_bib60","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","article-title":"Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2200866","article-title":"Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial","volume":"34","author":"Flohr","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"10.1016\/j.jaad.2026.01.075_bib62","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib63","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.01.075_bib64","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.075_bib65","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07.019","article-title":"Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: a population-based cohort study","volume":"154","author":"Tsai","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.075_bib66","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/bjd\/ljae342","article-title":"A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council","volume":"192","author":"Haag","year":"2024","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.075_bib67","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jaad.2022.01.018","article-title":"Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: interim results from the PEDISTAD Real-World Registry","volume":"87","author":"Paller","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226001271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226001271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:57:55Z","timestamp":1781715475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226001271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0190962226001271"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.01.075","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapies for atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.01.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}